171 related articles for article (PubMed ID: 29924669)
1. Treatment of Lymphatic Malformations with the mTOR Inhibitor Sirolimus: A Systematic Review.
Wiegand S; Wichmann G; Dietz A
Lymphat Res Biol; 2018 Aug; 16(4):330-339. PubMed ID: 29924669
[TBL] [Abstract][Full Text] [Related]
2. Topical rapamycin and microcystic lymphatic malformations.
Gu Y; Sebaratnam DF
J Am Acad Dermatol; 2024 Jan; 90(1):e29-e30. PubMed ID: 37717734
[No Abstract] [Full Text] [Related]
3. Pediatric case of acquired progressive lymphatic anomaly treated with sirolimus.
Komamizu S; Ozeki M; Hayashi D; Endo S; Hori-Hirose Y; Sasaki S; Ohnishi H
Pediatr Int; 2023 Jan; 65(1):e15497. PubMed ID: 36749179
[No Abstract] [Full Text] [Related]
4. Sirolimus for Pediatric Cervicofacial Lymphatic Malformation: A Systematic Review and Meta-Analysis.
Kamhieh Y; Mitra R; Burnett T; Jones H; Roblin G; Hall A
Laryngoscope; 2024 May; 134(5):2038-2047. PubMed ID: 37812168
[TBL] [Abstract][Full Text] [Related]
5. Verification of the efficacy of topical sirolimus gel for systemic rare vascular malformations: a pilot study.
Wataya-Kaneda M; Maeda S; Nakamura A; Hayashi M; Fujimoto M
J Dermatol; 2023 Dec; 50(12):1619-1624. PubMed ID: 37649426
[TBL] [Abstract][Full Text] [Related]
6. Targeted treatment in complex lymphatic anomaly: a case of synergistic efficacy of trametinib and sirolimus.
Seront E; Froidure A; Revencu N; Dekeuleneer V; Clapuyt P; Dumitriu D; Vikkula M; Boon LM
Orphanet J Rare Dis; 2024 May; 19(1):199. PubMed ID: 38750525
[TBL] [Abstract][Full Text] [Related]
7. Differences in Efficacy and Safety of Sirolimus and Sildenafil in Pediatric Lymphatic Malformations.
Wang J; Zhang X; Sun N; Liu Q; Li Y; Peng Y; Cheng X; Zhang J; Liu Y; Feng G; Liu Z; Ji T; Li X; Liu Y; Wang S; Ni X
Laryngoscope; 2023 Nov; 133(11):3192-3199. PubMed ID: 36861763
[TBL] [Abstract][Full Text] [Related]
8. Infectious complications of vascular anomalies treated with sirolimus: A systematic review.
Kalbfell R; Cohen-Cutler S; Grisham E; Bereitschaft C; Borst AJ; Green AM; Willis DN; Yaeger L; Blatt J; Sisk BA
Pediatr Blood Cancer; 2024 Jan; 71(1):e30758. PubMed ID: 37933207
[TBL] [Abstract][Full Text] [Related]
9. Real-World Data on the Use of Sirolimus in Asian Children with Vascular Malformations.
Yu L; Xu Z; Wei L; Zhang B; Qiu L; Ma L; Li L
Paediatr Drugs; 2024 May; 26(3):309-317. PubMed ID: 38280106
[TBL] [Abstract][Full Text] [Related]
10. Treatment of orbital lymphatic malformation with oral sirolimus: a case report.
Alba-Linero C; García-Lorente M; Rachwani-Anil R; Luque-Aranda G; Pérez-Cabeza MI; Escudero J
Arq Bras Oftalmol; 2022; 87(1):e20230072. PubMed ID: 35544942
[TBL] [Abstract][Full Text] [Related]
11. mTOR Pathway Substrates Present High Activation in Vascular Malformations and Significantly Decrease with Age.
Kopeć J; Sałacińska-Łoś E; Orzechowska M; Sokolnicka M; Gawłowska-Marciniak A; Przemysław P
Diagnostics (Basel); 2023 Dec; 14(1):. PubMed ID: 38201347
[TBL] [Abstract][Full Text] [Related]
12. Sirolimus experience in adult patients with vascular malformations.
Akyildiz A; Ismayilov R; Guven DC; Yildirim HC; Tatar OD; Kus F; Chalabiyev E; Turker FA; Dizdar O; Yalcin S; Gullu HI
Vascular; 2024 Mar; ():17085381241241853. PubMed ID: 38523367
[TBL] [Abstract][Full Text] [Related]
13. Clinical effectiveness and safety of sirolimus in pediatric patients with complex vascular anomalies: necessitating personalized and comprehensive approaches.
Kim M; Hong KT; Park HJ; Kim BK; Choi JY; Kim HY; Kang HJ
Front Pediatr; 2023; 11():1304133. PubMed ID: 38034833
[TBL] [Abstract][Full Text] [Related]
14. Genetic causes of lymphatic disorders: recent updates on the clinical and molecular aspects of lymphatic disease.
Bowman C; Rockson SG
Curr Opin Cardiol; 2024 May; 39(3):170-177. PubMed ID: 38483006
[TBL] [Abstract][Full Text] [Related]
15. Mixed lymphatic malformation of tongue in a child with excellent response to oral sirolimus.
Agrawal A; Kaur M; Bains A; Yadav T; Patra S
Indian J Dermatol Venereol Leprol; 2024 May; ():1-3. PubMed ID: 38841940
[No Abstract] [Full Text] [Related]
16. Topical rapamycin treatment for superficial microcystic lymphatic malformations.
Ugedo Alzaga J; Mendieta Eckert M; Villa-Gonzalez JM; Gonzalez-Hermosa MR
An Pediatr (Engl Ed); 2024 Jun; ():. PubMed ID: 38853059
[No Abstract] [Full Text] [Related]
17. Sequelae of surgery for lymphatic malformations.
Moreno-Alfonso JC; Triana-Junco PE; Miguel-Ferrero M; Díaz-González M; López-Gutiérrez JC
An Pediatr (Engl Ed); 2023 Oct; 99(4):266-267. PubMed ID: 37679216
[No Abstract] [Full Text] [Related]
18. Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: a monocentric prospective phase II study.
Hammer J; Seront E; Duez S; Dupont S; Van Damme A; Schmitz S; Hoyoux C; Chopinet C; Clapuyt P; Hammer F; Vikkula M; Boon LM
Orphanet J Rare Dis; 2018 Oct; 13(1):191. PubMed ID: 30373605
[TBL] [Abstract][Full Text] [Related]
19. The impact of sirolimus therapy on lesion size, clinical symptoms, and quality of life of patients with lymphatic anomalies.
Ozeki M; Nozawa A; Yasue S; Endo S; Asada R; Hashimoto H; Fukao T
Orphanet J Rare Dis; 2019 Jun; 14(1):141. PubMed ID: 31196128
[TBL] [Abstract][Full Text] [Related]
20. Treatment of voluminous and complicated superficial slow-flow vascular malformations with sirolimus (PERFORMUS): protocol for a multicenter phase 2 trial with a randomized observational-phase design.
Maruani A; Boccara O; Bessis D; Guibaud L; Vabres P; Mazereeuw-Hautier J; Barbarot S; Chiaverini C; Blaise S; Droitcourt C; Mallet S; Martin L; Lorette G; Woillard JB; Jonville-Bera AP; Rollin J; Gruel Y; Herbreteau D; Goga D; le Touze A; Leducq S; Gissot V; Morel B; Tavernier E; Giraudeau B;
Trials; 2018 Jun; 19(1):340. PubMed ID: 29945674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
